LBB Specialties and Meggle Excipients & Technology will work to distribute excipient products to companies in the American pharmaceutical and nutraceutical industries.
LeBaronBrown Specialties (LBB), a North American specialty chemical and ingredients distribution company, announced it entered into a strategic partnership on Aug. 1, 2019 with Meggle Excipients & Technology, a Wasserburg, Germany-based holding company in the dairy industry, to distribute its excipient products to companies in the American pharmaceutical and nutraceutical industries.
American International Chemical (AIC) and Charkit Chemical Company, LBB Specialties’ subsidiary companies, will handle the sales, marketing, and distribution efforts for Meggle products in the US market, according to an Aug. 27, 2019 press release.
Meggle provides the pharmaceutical industry with lactose-based excipients for direct compression and granulation tableting, powder preparations, and dry powder inhalation while investing sufficiently in R&D.
“Representing [Meggle] is a tremendous addition for Charkit and AIC,” said Jay Lang, president of Charkit Chemical, in the press release. “[Meggle] is one of only a handful of manufacturers of pharma-grade lactose excipients in the world, and they are well known for the excellent quality of their product portfolio, including value-added excipients for direct compression and inhalation applications.”
“The industry knowledge, customer focus, and broad-based capabilities offered by Charkit and AIC make them excellent partners for [Meggle],” said Ruth Leinenbach, director, BG Excipients and Technology at Meggle, in the press release. “The combination of our technical knowledge and the professional sales expertise of our new partners is a powerful recipe for success.”
Source: LBB Specialties
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.